Unknown

Dataset Information

0

Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells.


ABSTRACT: Hepatocellular carcinoma (HCC) is a heterogeneous malignancy related to diverse etiological factors. Different oncogenic mechanisms and genetic variations lead to multiple HCC molecular classifications. Recently, an immune-based strategy using immune checkpoint inhibitors (ICIs) was presented in HCC therapy, especially with ICIs against the programmed death-1 (PD-1) and its ligand PD-L1. However, despite the success of anti-PD-1/PD-L1 in other cancers, a substantial proportion of HCC patients fail to respond. In this review, we gather current information on biomarkers of anti-PD-1/PD-L1 treatment and the contribution of HCC heterogeneity and hepatic cancer stem cells (CSCs). Genetic variations of PD-1 and PD-L1 are associated with chronic liver disease and progression to cancer. PD-L1 expression in tumoral tissues is differentially expressed in CSCs, particularly in those with a close association with the tumor microenvironment. This information will be beneficial for the selection of patients and the management of the ICIs against PD-1/PD-L1.

SUBMITTER: Sukowati CHC 

PROVIDER: S-EPMC8316870 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10857830 | biostudies-literature
| S-EPMC7147660 | biostudies-literature
| S-EPMC4854782 | biostudies-literature
| S-EPMC8474294 | biostudies-literature
| S-EPMC6926111 | biostudies-literature
| S-EPMC8124544 | biostudies-literature
| S-EPMC8554719 | biostudies-literature
| S-EPMC5648155 | biostudies-literature
| S-EPMC9047987 | biostudies-literature
| S-EPMC8034578 | biostudies-literature